RT Journal Article SR Electronic T1 Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3727 OP 3737 DO 10.21873/anticanres.13521 VO 39 IS 7 A1 NGUYEN LINH TOAN A1 NGO THU HANG A1 NGUYEN KIM LUU A1 CAN VAN MAO A1 NGUYEN VAN BA A1 NGUYEN THI XUAN A1 TRUONG DINH CAM A1 NAOKI YAMAMOTO A1 HOANG VAN TONG A1 HO ANH SON YR 2019 UL http://ar.iiarjournals.org/content/39/7/3727.abstract AB Background/Aim: This study aims to investigate whether the combination of oncolytic viruses with chemoradiotherapy or other therapies is a promising strategy for cancer treatment. Materials and Methods: The anticancer effects of measles virus (MeV) in combination with nimotuzumab in the treatment of laryngeal cancer were evaluated in vitro and in nude mice inoculated with Hep2 tumors. MTT assay and flow cytometry were used to examine cell death. Results: Laryngeal cancer cells treated with MeV+nimotuzumab combination had a significantly lower survival rate compared to those treated with MeV or nimotuzumab alone (p<0.0001). In an animal model bearing human laryngeal tumor, the treated group had a higher survival rate (60%) compared to a untreated group (20%) (p<0.05), and the survival rate of the group treated with MeV+nimotuzumab combination was higher compared to the groups received single treatment. Conclusion: The MeV+nimotuzumab combination has greater anticancer activities in both laryngeal cancer cells and an animal model.